Baxalta (NYSE:BXLT) Earning Somewhat Positive Press Coverage, Report Shows

Headlines about Baxalta (NYSE:BXLT) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxalta earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.9319987448249 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Baxalta (BXLT) traded down 0.39% during trading on Friday, reaching $46.02. The company’s stock had a trading volume of 228,648,358 shares. Baxalta has a 52-week low of $37.44 and a 52-week high of $46.52. The stock has a 50-day moving average of $46.02 and a 200-day moving average of $46.02.

TRADEMARK VIOLATION WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/09/23/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-baxalta-bxlt-share-price.html.

Baxalta Company Profile

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR.

Insider Buying and Selling by Quarter for Baxalta (NYSE:BXLT)

Receive News & Ratings for Baxalta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply